RT Journal Article
SR Electronic
T1 Facilitating safe discharge through predicting disease progression in moderate COVID-19: a prospective cohort study to develop and validate a clinical prediction model in resource-limited settings
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.02.21267170
DO 10.1101/2021.12.02.21267170
A1 Chandna, Arjun
A1 Mahajan, Raman
A1 Gautam, Priyanka
A1 Mwandigha, Lazaro
A1 Gunasekaran, Karthik
A1 Bhusan, Divendu
A1 Cheung, Arthur T L
A1 Day, Nicholas
A1 Dittrich, Sabine
A1 Dondorp, Arjen
A1 Geevar, Tulasi
A1 Ghattamaneni, Srinivasa R
A1 Hussain, Samreen
A1 Jimenez, Carolina
A1 Karthikeyan, Rohini
A1 Kumar, Sanjeev
A1 Kumar, Shiril
A1 Kumar, Vikash
A1 Kundu, Debasree
A1 Lakshmanan, Ankita
A1 Manesh, Abi
A1 Menggred, Chonticha
A1 Moorthy, Mahesh
A1 Osborn, Jennifer
A1 Richard-Greenblatt, Melissa
A1 Sharma, Sadhana
A1 Singh, Veena K
A1 Singh, Vikash K
A1 Suri, Javvad
A1 Suzuki, Shuichi
A1 Tubprasert, Jaruwan
A1 Turner, Paul
A1 Villanueva, Annavi M G
A1 Waithira, Naomi
A1 Kumar, Pragya
A1 Varghese, George M
A1 Koshiaris, Constantinos
A1 Lubell, Yoel
A1 Burza, Sakib
YR 2021
UL http://medrxiv.org/content/early/2021/12/07/2021.12.02.21267170.abstract
AB Background In locations where few people have received COVID-19 vaccines, health systems remain vulnerable to surges in SARS-CoV-2 infections. Tools to identify patients suitable for community-based management are urgently needed.Methods We prospectively recruited adults presenting to two hospitals in India with moderate symptoms of laboratory-confirmed COVID-19 in order to develop and validate a clinical prediction model to rule-out progression to supplemental oxygen requirement. The primary outcome was defined as any of the following: SpO2 < 94%; respiratory rate > 30 bpm; SpO2/FiO2 < 400; or death. We specified a priori that each model would contain three clinical parameters (age, sex and SpO2) and one of seven shortlisted biochemical biomarkers measurable using near-patient tests (CRP, D-dimer, IL-6, NLR, PCT, sTREM-1 or suPAR), to ensure the models would be suitable for resource-limited settings. We evaluated discrimination, calibration and clinical utility of the models in a temporal external validation cohort.Findings 426 participants were recruited, of whom 89 (21·0%) met the primary outcome. 257 participants comprised the development cohort and 166 comprised the validation cohort. The three models containing NLR, suPAR or IL-6 demonstrated promising discrimination (c-statistics: 0·72 to 0·74) and calibration (calibration slopes: 1·01 to 1·05) in the validation cohort, and provided greater utility than a model containing the clinical parameters alone.Interpretation We present three clinical prediction models that could help clinicians identify patients with moderate COVID-19 suitable for community-based management. The models are readily implementable and of particular relevance for locations with limited resources.Funding Médecins Sans Frontières, India.Evidence before this study A living systematic review by Wynants et al. identified 137 COVID-19 prediction models, 47 of which were derived to predict whether patients with COVID-19 will have an adverse outcome. Most lacked external validation, relied on retrospective data, did not focus on patients with moderate disease, were at high risk of bias, and were not practical for use in resource-limited settings. To identify promising biochemical biomarkers which may have been evaluated independently of a prediction model and therefore not captured by this review, we searched PubMed on 1 June 2020 using synonyms of “SARS-CoV-2” AND [“biomarker” OR “prognosis”]. We identified 1,214 studies evaluating biochemical biomarkers of potential value in the prognostication of COVID-19 illness. In consultation with FIND (Geneva, Switzerland) we shortlisted seven candidates for evaluation in this study, all of which are measurable using near-patient tests which are either currently available or in late-stage development.Added value of this study We followed the TRIPOD guidelines to develop and validate three promising clinical prediction models to help clinicians identify which patients presenting with moderate COVID-19 can be safely managed in the community. Each model contains three easily ascertained clinical parameters (age, sex, and SpO2) and one biochemical biomarker (NLR, suPAR or IL-6), and would be practical for implementation in high-patient-throughput low resource settings. The models showed promising discrimination and calibration in the validation cohort. The inclusion of a biomarker test improved prognostication compared to a model containing the clinical parameters alone, and extended the range of contexts in which such a tool might provide utility to include situations when bed pressures are less critical, for example at earlier points in a COVID-19 surge.Implications of all the available evidence Prognostic models should be developed for clearly-defined clinical use-cases. We report the development and temporal validation of three clinical prediction models to rule-out progression to supplemental oxygen requirement amongst patients presenting with moderate COVID-19. The models are readily implementable and should prove useful in triage and resource allocation. We provide our full models to enable independent validation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by MSF, India, who maintained a sponsor/investigator role for the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was given by the AIIMS, Patna Ethics Committee; CMC Ethics Committee; Oxford Tropical Research Ethics Committee; and MSF Ethical Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified, individual participant data from this study will be available to researchers whose proposed purpose of use is approved by the data access committees at M&eacutedecins Sans Fronti&egraveres and the Mahidol-Oxford Tropical Medicine Research Unit. Inquiries or requests for the data may be sent to data.sharing@london.msf.org and datasharing@tropmedres.ac. Researchers interested in accessing biobanked samples should contact the corresponding authors who will coordinate with the respective institutions. https://osf.io/dxq43/